Lomefloxacin - Novartis Ophthalmics

Drug Profile

Lomefloxacin - Novartis Ophthalmics

Alternative Names: Okacyn

Latest Information Update: 03 Apr 2008

Price : $50

At a glance

  • Originator Abbott Japan
  • Developer Novartis Ophthalmics
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Infectious conjunctivitis

Most Recent Events

  • 28 Feb 2003 Dainabot has merged with Hokuriku Seiyaku to form Abbott Japan
  • 03 Apr 2001 Launched for Conjunctivitis in Spain (Ophthalmic)
  • 25 Aug 2000 Registered for Conjunctivitis in Spain (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top